Broad Humoral and Cellular Immunity Elicited by One-Dose mRNA Vaccination 18 Months after SARS-CoV-2 Infection

The authors showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months.